InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,213.20
(
-0.10%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.14
(
-0.38%
)
Bitcoin
70,038.37
(
-0.13%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 190027

Friday, 05/01/2015 7:50:38 AM

Friday, May 01, 2015 7:50:38 AM

Post# of 251889
TEVA 1Q15 results, Copaxone figures:

In the United States, sales of Copaxone® amounted to $732 million, a decrease of 10% compared to the first quarter of 2014. At the end of the first quarter of 2015, according to March 2015 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 31.9% and 30.6%, respectively. Copaxone® 40 mg/mL accounted for 66% of total Copaxone® prescriptions in the U.S.


http://www.tevapharm.com/news/?itemid=%7BD87D2E15-5538-47FF-8ACB-5392030889BC%7D
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up